- Home
- BHST vs ALGS Comparison
BHST vs ALGS Comparison
Compare BHST & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHST | ALGS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 34.6M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BHST | ALGS |
|---|---|---|
| Price | $2.05 | $5.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $39.33 |
| AVG Volume (30 Days) | 43.7K | ★ 100.6K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $146.27 | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $3.98 |
| 52 Week High | $12.80 | $13.69 |
Technical Indicators
Market Signals| Indicator | BHST | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 45.47 |
| Support Level | $1.82 | $4.80 |
| Resistance Level | $2.99 | $5.94 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 13.51 | 15.16 |
Price Performance
Historical ComparisonAbout BHST BioHarvest Sciences Inc.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.